Today: 18 November 2025
Subscribe
Browse Category

Psychedelics News 27 August 2025 - 4 November 2025

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

Below is a full breakdown of COMPASS Pathways’ recent performance, news, expert commentary, industry positioning, and an analysis of the stock’s fundamentals, technicals, and future scenarios. Stock Performance Overview (Nov 2025) COMPASS Pathways’ stock has experienced considerable volatility in 2025, mirroring the company’s clinical trial news cycle. As of November 4, 2025, CMPS trades in the mid-$5 range (around $5.95–$6.00), roughly flat versus a week prior intellectia.ai. This price is well above its summertime lows, but slightly off the highs reached in October. Recent Trading Range: In mid-October 2025, CMPS rallied to $6.76 per share, marking a new 52-week high
4 November 2025
 ·  ·  ·  ·  · 
Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Stock Surge & Analyst Reaction Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech (versus ~$5.48 offering price). In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a week of good news: BPL-003’s FDA breakthrough, plus well-received capital raise plans. Volume on Oct. 17 was very high (tens of millions of shares), reflecting heavy trading. Over 2025 the stock has skyrocketed ~348% ts2.tech, making ATAI one of the year’s top biotech performers. Its market cap now hovers around $1.2 billion ts2.tech. Analysts have taken notice. Needham Research just initiated
18 October 2025
 ·  ·  ·  ·  · 
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

Key Facts – October 18, 2025 MNMD Stock Rallies to New Highs on Heavy Volume MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 on unusually heavy volume ts2.tech. After a brief mid-week pullback on profit-taking (shares dipped ~4% intraday on Oct. 16) ts2.tech, MNMD roared back by week’s end – closing at $13.65 on Friday, Oct. 17, a one-day gain of +14.6% investing.com. This rally has propelled MindMed to roughly +68% YTD returns ts2.tech, a remarkable run fueled
18 October 2025
 ·  ·  ·  ·  ·  ·  · 
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

Stock Soars to 52-Week High on Investor Hype MindMed’s stock has been on fire in recent weeks, vastly outperforming the broader market. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 with unusually heavy trading volume marketbeat.com. Just a couple of weeks earlier, on September 29, MNMD spiked 12.8% in a single session, hitting ~$12.04 by day’s end allpennystocks.com. These sharp gains have propelled MindMed to roughly +68% year-to-date returns finance.yahoo.com, a remarkable run driven by excitement over its clinical progress. Investor sentiment is clearly bullish. The stock’s rally has been supported by
18 October 2025
 ·  ·  ·  ·  · 
Go toTop